Ema, Inc.

Ema, Inc. company information, Employees & Contact Information

Explore related pages

Related company profiles:

Starting in 1975, EMA focused on automation technology for water and wastewater utilities. We’ve added new services over the decades to meet our clients’ changing needs, including new practice areas and offices throughout the United States and Canada. As an employee-owned company, we are invested in successful results for our clients. Today EMA works with utilities and municipalities to improve business processes and work practices, enabled by technology and organizational change. We deliver innovative solutions to help our clients lower costs, increase productivity, improve customer service, and maximize return on investment.
Looking for a particular Ema, Inc. employee's phone or email?

Ema, Inc. Questions

News

OS Therapies Provides Positive EMA Regulatory Update Following Positive Rapporteur Meeting - Newsfile

OS Therapies Provides Positive EMA Regulatory Update Following Positive Rapporteur Meeting Newsfile

Emera Inc (EMA) Q2 2025 Earnings Call Highlights: Strong EPS Growth and Strategic Capital Deployment - Yahoo Finance

Emera Inc (EMA) Q2 2025 Earnings Call Highlights: Strong EPS Growth and Strategic Capital Deployment Yahoo Finance

Brooke EMA receives boost from gas company - weirtondailytimes.com

Brooke EMA receives boost from gas company weirtondailytimes.com

Annexon Selected by EMA to Participate in Product Development Coordinator Pilot for Vonaprument (ANX007) for Dry Age-Related Macular Degeneration with Geographic Atrophy - GlobeNewswire

Annexon Selected by EMA to Participate in Product Development Coordinator Pilot for Vonaprument (ANX007) for Dry Age-Related Macular Degeneration with Geographic Atrophy GlobeNewswire

Emera Incorporated Announces Results of Series A and Series B First Preferred Shares Conversion - Business Wire

Emera Incorporated Announces Results of Series A and Series B First Preferred Shares Conversion Business Wire

Soleno Therapeutics, Inc. (SLNO) Targets EMA Approval as U.S. Launch of VYKAT XR Expands - Insider Monkey

Soleno Therapeutics, Inc. (SLNO) Targets EMA Approval as U.S. Launch of VYKAT XR Expands Insider Monkey

The European Medicines Agency (EMA) Has Approved an Additional Subcutaneous Administration Option for TAKHZYRO® (lanadelumab) for Patients Aged 12 Years and Above with Recurrent Attacks of Hereditary Angioedema (HAE) - PR Newswire

The European Medicines Agency (EMA) Has Approved an Additional Subcutaneous Administration Option for TAKHZYRO® (lanadelumab) for Patients Aged 12 Years and Above with Recurrent Attacks of Hereditary Angioedema (HAE) PR Newswire

Emera Incorporated (TSE:EMA) is a favorite amongst institutional investors who own 55% - Yahoo Finance

Emera Incorporated (TSE:EMA) is a favorite amongst institutional investors who own 55% Yahoo Finance

CEO: I love Texas. But the state's abortion ban means I'm moving my company. - Houston Chronicle

CEO: I love Texas. But the state's abortion ban means I'm moving my company. Houston Chronicle

Biogen Inc. Announces FDA and EMA Acceptance of Higher Dose Regimen for Nusinersen in Spinal Muscular Atrophy - Quiver Quantitative

Biogen Inc. Announces FDA and EMA Acceptance of Higher Dose Regimen for Nusinersen in Spinal Muscular Atrophy Quiver Quantitative

Emera Incorporated Announces Conversion Privilege of Cumulative Rate Reset First Preferred Shares, Series A and Cumulative Floating Rate First Preferred Shares, Series B - Business Wire

Emera Incorporated Announces Conversion Privilege of Cumulative Rate Reset First Preferred Shares, Series A and Cumulative Floating Rate First Preferred Shares, Series B Business Wire

Hoth Therapeutics, Inc. (HOTH) Files EMA Application for Global Expansion of HT-001 Skin Therapy - Insider Monkey

Hoth Therapeutics, Inc. (HOTH) Files EMA Application for Global Expansion of HT-001 Skin Therapy Insider Monkey

Read This Before Judging Emera Incorporated's (TSE:EMA) ROE - Yahoo Finance

Read This Before Judging Emera Incorporated's (TSE:EMA) ROE Yahoo Finance

Quoin Pharmaceuticals Announces European Medicines Agency (EMA) Grants Orphan Drug Designation for QRX003 for the Treatment of Netherton Syndrome - GlobeNewswire

Quoin Pharmaceuticals Announces European Medicines Agency (EMA) Grants Orphan Drug Designation for QRX003 for the Treatment of Netherton Syndrome GlobeNewswire

Emera to Commence Trading on the New York Stock Exchange - Business Wire

Emera to Commence Trading on the New York Stock Exchange Business Wire

EMA Gives Positive Opinion on Zoetis Inc. (ZTS)’ Cat Arthritis Therapy, Portela - Yahoo Finance

EMA Gives Positive Opinion on Zoetis Inc. (ZTS)’ Cat Arthritis Therapy, Portela Yahoo Finance

FDA Grants Priority Review for Biologics License Application (BLA) and EMA Accepts Marketing Authorisation Application (MAA) for Apitegromab as a Treatment for Spinal Muscular Atrophy - Business Wire

FDA Grants Priority Review for Biologics License Application (BLA) and EMA Accepts Marketing Authorisation Application (MAA) for Apitegromab as a Treatment for Spinal Muscular Atrophy Business Wire

Emera Inc (TSX:EMA) Q1 2025: Everything You Need To Know Ahead Of Earnings - Yahoo Finance

Emera Inc (TSX:EMA) Q1 2025: Everything You Need To Know Ahead Of Earnings Yahoo Finance

GeoVax Highlights EMA Regulatory Milestone as Catalyst for Near-Term Revenue from GEO-MVA Mpox Vaccine - Yahoo Finance

GeoVax Highlights EMA Regulatory Milestone as Catalyst for Near-Term Revenue from GEO-MVA Mpox Vaccine Yahoo Finance

An Intrinsic Calculation For Emera Incorporated (TSE:EMA) Suggests It's 29% Undervalued - Yahoo Finance

An Intrinsic Calculation For Emera Incorporated (TSE:EMA) Suggests It's 29% Undervalued Yahoo Finance

Willow Introduces Ema, the Revolutionary AI Solution Supporting the Maternal and Postpartum Wellness Journey - PR Newswire

Willow Introduces Ema, the Revolutionary AI Solution Supporting the Maternal and Postpartum Wellness Journey PR Newswire

AI Startup Ema Wants to Create a ‘Universal Employee’ - Inc.com

AI Startup Ema Wants to Create a ‘Universal Employee’ Inc.com

RemeGen's Telitacicept (RC18) Received Orphan Drug Designation from EMA for Myasthenia Gravis - PR Newswire

RemeGen's Telitacicept (RC18) Received Orphan Drug Designation from EMA for Myasthenia Gravis PR Newswire

X4 Pharmaceuticals Announces EMA Validation of Marketing Authorization Application (MAA) for Mavorixafor - licenced to Norgine for commercialisation in Europe. - PR Newswire

X4 Pharmaceuticals Announces EMA Validation of Marketing Authorization Application (MAA) for Mavorixafor - licenced to Norgine for commercialisation in Europe. PR Newswire

Ema Secures $50 Million in Series A - The SaaS News

Ema Secures $50 Million in Series A The SaaS News

EMA Partners IPO opens for subscription. Check key dates, GMP, price band and subscription - The Economic Times

EMA Partners IPO opens for subscription. Check key dates, GMP, price band and subscription The Economic Times

Emera (TSE:EMA) Is Paying Out A Larger Dividend Than Last Year - Yahoo Finance

Emera (TSE:EMA) Is Paying Out A Larger Dividend Than Last Year Yahoo Finance

EMA provides positive ATMP opinion for gene therapy products OCU410 and OCU410ST - Ophthalmology Times Europe

EMA provides positive ATMP opinion for gene therapy products OCU410 and OCU410ST Ophthalmology Times Europe

Ocugen, Inc. Announces Positive Scientific Advice from the European Medicines Agency Related to the Approval Pathway for OCU410ST—Modifier Gene Therapy for Stargardt Disease - Ocugen

Ocugen, Inc. Announces Positive Scientific Advice from the European Medicines Agency Related to the Approval Pathway for OCU410ST—Modifier Gene Therapy for Stargardt Disease Ocugen

Ema raises $36M to build universal AI employees for enterprises - Venturebeat

Ema raises $36M to build universal AI employees for enterprises Venturebeat

Ema increases its Series A to $50M, with new funding led by Accel and Section 32 - PRWeb

Ema increases its Series A to $50M, with new funding led by Accel and Section 32 PRWeb

Actuate Therapeutics Provides FDA with Updated Clinical - GlobeNewswire

Actuate Therapeutics Provides FDA with Updated Clinical GlobeNewswire

Alphabet Stock Holds $170 Support With Bullish Signals From 20 EMA (Technical Analysis) - Seeking Alpha

Alphabet Stock Holds $170 Support With Bullish Signals From 20 EMA (Technical Analysis) Seeking Alpha

Sarepta Therapeutics (SRPT) Declines Again On EMA - GlobeNewswire

Sarepta Therapeutics (SRPT) Declines Again On EMA GlobeNewswire

Emera Incorporated Announces Dividend Rates for Series A and Series B First Preferred Shares - Business Wire

Emera Incorporated Announces Dividend Rates for Series A and Series B First Preferred Shares Business Wire

Soleno Therapeutics Announces Submission and EMA Validation of Marketing Authorization Application for Diazoxide Choline Prolonged-Release Tablets for the Treatment of Hyperphagia in Patients with Prader-Willi Syndrome - GlobeNewswire

Soleno Therapeutics Announces Submission and EMA Validation of Marketing Authorization Application for Diazoxide Choline Prolonged-Release Tablets for the Treatment of Hyperphagia in Patients with Prader-Willi Syndrome GlobeNewswire

AriBio Receives EMA Phase 3 Clinical Trial Authorisation for AR1001 in Treatment of Alzheimer’s Disease (POLARIS-AD) - Business Wire

AriBio Receives EMA Phase 3 Clinical Trial Authorisation for AR1001 in Treatment of Alzheimer’s Disease (POLARIS-AD) Business Wire

Ema Transforms Enterprise AI with $50M Funding, Persona Builder, and On-Prem Deployment - AIM Media House

Ema Transforms Enterprise AI with $50M Funding, Persona Builder, and On-Prem Deployment AIM Media House

Celltrion applies for EMA approval of smaller dose formulation of Yuflyma - The Korea Economic Daily Global Edition

Celltrion applies for EMA approval of smaller dose formulation of Yuflyma The Korea Economic Daily Global Edition

Insmed Receives Priority Medicines (PRIME) Designation from European Medicines Agency (EMA) for Brensocatib in Patients with Non-Cystic Fibrosis Bronchiectasis (NCFBE) - PR Newswire

Insmed Receives Priority Medicines (PRIME) Designation from European Medicines Agency (EMA) for Brensocatib in Patients with Non-Cystic Fibrosis Bronchiectasis (NCFBE) PR Newswire

GenAI startup Ema secures $25 million in funding led by Accel, Prosus - The Economic Times

GenAI startup Ema secures $25 million in funding led by Accel, Prosus The Economic Times

Emera Incorporated (EMA-T) Profile - The Globe and Mail

Emera Incorporated (EMA-T) Profile The Globe and Mail

EMA approves Janssen’s Prezista continuous manufacturing line - European Pharmaceutical Review

EMA approves Janssen’s Prezista continuous manufacturing line European Pharmaceutical Review

Meet the PhD of ACD - Hagerty

Meet the PhD of ACD Hagerty

Dr. Mark Bell Announces EMA Named to Inc. 5000 Fastest-Growing Private Companies in America for Fourth Consecutive Year - PRWeb

Dr. Mark Bell Announces EMA Named to Inc. 5000 Fastest-Growing Private Companies in America for Fourth Consecutive Year PRWeb

Top Ema, Inc. Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant